Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

Rhea-AI Summary

Clearmind Medicine Inc. (Nasdaq: CMND) secures global rights to innovative psychedelic compounds for PTSD treatment through an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. The global market for PTSD treatment is projected to reach $27.37 billion by 2033. Clearmind aims to revolutionize mental health care with these novel compounds, offering hope to millions worldwide.

Positive

• Exclusive global rights secured for innovative psychedelic compounds for treating PTSD and other mental health conditions.

• Potential to revolutionize mental health care with promising compounds for complex conditions like PTSD.

• Strategic collaboration with Yissum Research Development Company of the Hebrew University, a world-leading institution.

• Access to a lucrative market valued at $16.8 billion in 2023, expected to grow to $27.37 billion by 2033.

• Future milestone payments, royalties, and intellectual property safeguards included in the agreement.

Negative

• None.

Biotechnology Analyst

Clearmind Medicine's acquisition of exclusive global rights to novel psychedelic compounds for PTSD treatment can be seen as a strategic move in the biotech industry where innovation is key to growth and differentiation. PTSD is a difficult condition to treat effectively with current therapies often having limited efficacy and substantial side effects. By securing a patent licensing agreement with Yissum, Clearmind gains access to potentially groundbreaking research that could enable them to develop more effective treatments with fewer side effects, leveraging the reputability of the Hebrew University and the inventors’ expertise. Considering the predicted growth of the PTSD treatment market, Clearmind positions itself at the forefront of a niche yet expanding sector. The success of Clearmind's endeavors will hinge on their ability to navigate the rigorous clinical trial process, regulatory approvals and ultimately, the commercial viability of the compounds. While the promise of new treatments is compelling, Clearmind's path to market is laden with scientific, regulatory and financial challenges that could affect the timeline and success of product launches. Investors should not overlook the considerable time and capital required to bring such novel therapeutics to market.

Financial Analyst

The financial implications of Clearmind's exclusive licensing agreement are multifaceted. On one hand, access to innovative compounds for a growing market such as PTSD treatment could offer substantial revenue opportunities. The company's commitment to milestone payments and royalties indicates a performance-based agreement, which aligns with prudent financial planning, as it suggests Clearmind’s payouts are contingent upon developmental progress and future sales performance. However, the cost of ongoing development and meeting regulatory guidelines typically requires significant investment. The potential for high R&D expenses and the time required before any revenues from sales materialize could strain the company's finances in the short to medium term. Investors should weigh the potential long-term benefits against the inherent risks of investing in clinical-stage biotech companies, including the possibility of delayed or failed regulatory approvals. Examining the company’s cash flow and existing capital will be important in assessing whether Clearmind has the financial resilience to support the extended period of drug development and commercialization that lies ahead.

Mental Health Expert

From a mental health perspective, the entry of novel, psychedelic-derived compounds into the PTSD treatment landscape is noteworthy. PTSD is a complex condition and the shortcomings of current treatments such as SSRIs and SNRIs highlight a significant unmet need. If the compounds under Clearmind's new license demonstrate favorable safety and efficacy profiles, they could represent a paradigm shift in treating PTSD and related conditions. This could improve the quality of life for millions afflicted with mental health conditions and reduce the overall societal and economic burden of these diseases. Nevertheless, patient and practitioner acceptance of psychedelic-based treatments will be critical to adoption. Precedent and ongoing public and academic discourse on the therapeutic potential of psychedelics may positively influence acceptance. The innovative approach could also pave the way for further research into other mental health disorders, expanding the potential implications of the compounds beyond PTSD.

Vancouver, Canada, May 07, 2024 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement provides Clearmind with exclusive global rights to further develop, manufacture, and commercialize innovative compounds invented by Professors Rami Yaka, Ahmed Masaewa and Avi Priel from the Hebrew University. These novel compounds are targeted at treating post-traumatic stress disorder (PTSD) and other mental health conditions.

The global market for PTSD treatment, valued at $16.8 billion in 2023, is expected to reach $27.37 billion by 2033, according to Future Market Insights. Existing treatment options like SSRIs and SNRIs offer limited efficacy and are often accompanied by side effects including nausea, weight gain, sexual dysfunction, insomnia and increased anxiety.

Dr. Adi Zullof-Shani, CEO of Clearmind, stated, "We are excited to announce this groundbreaking patent license agreement, which reflects our strong collaboration with Yissum and the Hebrew University, a world-leading institution. This agreement marks a significant stride in our mission to meet urgent mental health care needs. We believe that the psychedelic compounds covered by this agreement hold immense promise in treating complex conditions like PTSD, offering a new ray of hope to millions of people worldwide."

Under the terms of the agreement, Clearmind receives exclusive rights to develop, manufacture, and commercialize novel compounds for treating PTSD and other mental health disorders. Clearmind is responsible for the ongoing development and potential commercialization in line with regulatory guidelines.The agreement includes future milestone payments, royalties on future sales, and commitments to safeguard intellectual property rights.

About Yissum
Yissum is the technology transfer company of the Hebrew University of Jerusalem. Founded in 1964, Yissum serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum’s mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. The company has registered more than 11,680 patents globally, licensed over 1,160 technologies, and has spun out over 260 companies. Yissum’s business partners span the globe. For further information please visit www.yissum.co.il.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of sixteen patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”

For further information visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com

General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its mission to meet urgent mental health care needs and its belief that that the psychedelic compounds covered by patent licensing agreement hold immense promise in treating complex conditions like PTSD, offering a new ray of hope to millions of people worldwide. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

FAQ

What did Clearmind Medicine secure exclusive global rights to?

Clearmind Medicine secured exclusive global rights to breakthrough psychedelic compounds for PTSD treatment through a patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.

What is the stock symbol for Clearmind Medicine Inc.?

The stock symbol for Clearmind Medicine Inc. is CMND.

Who are the inventors of the innovative compounds licensed by Clearmind Medicine?

Professors Rami Yaka, Ahmed Masaewa, and Avi Priel from the Hebrew University are the inventors of the innovative compounds licensed by Clearmind Medicine.

What is the market value of PTSD treatment in 2023 and the projected value by 2033?

The market value of PTSD treatment was $16.8 billion in 2023, and it is projected to reach $27.37 billion by 2033.

What are the limitations of existing treatment options for PTSD mentioned in the press release?

Existing treatment options like SSRIs and SNRIs offer efficacy and are often accompanied by side effects including nausea, weight gain, sexual dysfunction, insomnia, and increased anxiety.